Bionomics Signs Option and License Agreement With Merck

Bionomics Signs Option and License Agreement With Merck

Research Will Focus on Discovery of New Pain Treatments

ADELAIDE, South Australia, July 31, 2013 (GLOBE NEWSWIRE) -- Bionomics Limited
(ASX:BNO) today announced an agreement with Merck, known as MSD outside the
United States and Canada, to discover and develop novel small molecule
candidates for the treatment of chronic pain, including neuropathic pain.

Under the terms of the agreement, Merck will have the option to exclusively
license a compound from Bionomics for development and commercialisation. In
return, Bionomics may receive option exercise fees and development and
regulatory milestone payments of up to US$172 million. Bionomics may also be
eligible for undisclosed royalties on net sales of products from the
collaboration. Bionomics retains the right to develop and commercialise
certain compounds for which Merck does not exercise its option. The initial
period of the research program will be two years.

Dr Deborah Rathjen, CEO & Managing Director of Bionomics, said, "We are very
excited to be working with Merck to define new therapies for chronic and
neuropathic pain. Bionomics is continuing to deliver on its business model of
strategic partnering for the development and commercialisation of selected
programs within its pipeline."

Bionomics will use its ionX drug discovery platform and MultiCore chemistry to
identify potential drug candidates.

Dr Sue O'Connor, Bionomics' VP Neuroscience Research, commented, "Merck is a
global pharmaceutical company and this research collaboration is a strong
validation of our drug discovery platforms."

The global pain treatment market recorded sales of US$22 billion in 2010.
However, as patent expiries loom, the global market value is anticipated by
some analysts to contract to US$18.7 billion by 2016. Within the global pain
market the neuropathic pain market is expected to grow from US$2.4 billion in
2010 to reach US$3.6 billion by 2020. (The Pain Outlook to 2013, Scrip
Business Insights 2011)
About Bionomics Limited

Bionomics (ASX:BNO) is an Australian based international biotechnology company
which discovers and develops innovative therapeutics for cancer and diseases
of the central nervous system. Bionomics has small molecule and antibody
product development programs in the areas of cancer, anxiety, and memory loss.
Its oncology approach includes cancer stem cell therapeutics as well as
vascular disruption in solid tumours.

BNC105, which is undergoing Phase II clinical development in a range of solid
tumour types, is based upon the identification of a novel compound that
potently and selectively restricts blood flow within tumours. BNC105 offers
blockbuster potential if successfully developed. A clinical program is also
underway for the treatment of anxiety disorders and depression based on
IW-2143(BNC210), a novel compound which stimulates neurite outgrowth. IW-2143
is partnered with Ironwood Pharmaceuticals.

Bionomics' discovery and development activities are driven by its four
proprietary technology platforms: Angene®, a drug discovery platform which
incorporates a variety of genomics tools to identify and validate novel
angiogenesis targets (involved in the formation of new blood vessels);
MultiCore®, a diversity orientated chemistry platform for the discovery of
small molecule drugs; ionX® , a set of novel technologies for the
identification of drugs targeting ion channels for diseases of the central
nervous system; and CSC Rx Discovery™, which identifies antibody and small
molecule therapeutics that inhibit the growth of cancer stem cells. These
platforms drive Bionomics' pipeline and underpin its established business
strategy of securing partners for its key compounds.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of
the United States' Private Securities Litigation Reform Act of 1995. Any
statements contained in this presentation that relate to prospective events or
developments, including, without limitation, statements made regarding
Bionomics' development candidates BNC105, IW-2143 (BNC210), BNC101 and BNC375,
our acquisition of Eclipse Therapeutics and ability to develop products from
their platform, its licensing deal with Ironwood Pharmaceuticals, drug
discovery programs and pending patent applications are deemed to be
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "projects," "forecasts," "will" and similar expressions are
intended to identify forward-looking statements. There are a number of
important factors that could cause actual results or events to differ
materially from those indicated by these forward-looking statements, including
risks related to our available funds or existing funding arrangements, a
downturn in our customers' markets, our failure to introduce new products or
technologies in a timely manner, Ironwood's decisions to continue or not
continue development of IW-2143, regulatory changes, risks related to our
international operations, our inability to integrate acquired businesses and
technologies into our existing business and to our competitive advantages, as
well as other factors. Results of studies performed on competitors products
may vary from those reported when tested in different settings. Subject to the
requirements of any applicable legislation or the listing rules of any stock
exchange on which our securities are quoted, we disclaim any intention or
obligation to update any forward-looking statements as a result of
developments occurring after the date of this announcement.

CONTACT: FOR FURTHER INFORMATION PLEASE CONTACT:
        
         Bionomics Limited

         Dr Deborah Rathjen
         CEO & Managing Director
         +618 8354 6101 /
         0418 160 425
         drathjen@bionomics.com.au
        
         Monsoon Communications

         Rudi Michelson
         +613 9620 3333
         rudim@monsoon.com.au
        
         The Trout Group

         Lauren Glaser
         +1 646 378 2972
         lglaser@troutgroup.com